DNA修复基因XPD遗传多态性与肺癌易感性关系的meta分析

The Association between Polymorphisms of XPD and Susceptibility of Lung Cancer:A meta Analysis

背景与目的研究表明DNA损伤修复基因-人类着色性干皮病基因D(xeroderma pigmentosum group D,XPD)多态性与肺癌的易感性有关,但各研究结论不一,本研究拟通过meta分析,定量地评价XPD312和751位点基因多态性与肺癌的关系。方法全面检索相关文献,按纳入标准对文献进行筛选后提取相关信息,然后在Stata10软件中按照meta分析流程,选择合适方法计算合并的OR值及95%可信区间,并进行敏感性分析和发表偏倚的估计。结果本研究纳入国内外22篇合格文献,其中XPD312位点15篇,XPD751位点20篇。合并结果显示,携带XPD312Asn/Asn突变基因型患肺癌的危险性是野生型Asp/Asp的1.18倍(95%CI:1.03-1.34,P=0.018);XPD751位点突变基因型也与肺癌危险性升高有关(Lys/GlnOR=1.09,95%CI:1.02-1.18;Gln/GlnOR=1.24,95%CI:1.10-1.41)。亚组分析显示XPD751与肺癌的关联性仅见于欧美人群。漏斗图和Egger’s回归分析均未发现明显的偏倚。结论XPD基因312和751位点的突变与肺癌的易感性升高有关。

Background and objective Many studies concluded that the polymorphisms of XPD were involved in the risk of lung cancer. However, several other studies suggested no association. To explore whether the polymorphisms of XPD contribute to the genetic susceptibility to lung cancer, we carried a meta-analysis based on the published works. Methods All works related to XPD and lung cancer risk were searched and carefully selected. The genotYPe frequencies of XPD and related variables were abstracted and the pooled ORs were calculated after the heterogeneity test with the software Stata 10. Publication bias and sensitivity were evaluated at the same time. Results Twenty-two studies were included according to the selection criteria, of which fifteen investigated the codon 312 of XPD and twenty studied the codon 75L The pooled OR of susceptibility to lung cancer with XPD312 Ash/ASh genotype compared to the wild Asp/Asp were 1.18 （95%CI： 1.03-1.34, P=0.018）. And the polymorphisms ofXPD codon 751 were also associated with increased lung cancer risk （Lys/Gln OR=1.09, 95%CI： 1.02-1.18; Gln/Gln OR=1.24, 95%CI： 1.10-1.41）. However, subgroup analysis indicated that the association between XPD751 and lung cancer could only be found in Europeans and Americans. The publication bias analysis had no statistically significant results. Conclusion Polymorphisms of XPD codons 312 and 751 seem to be involved in elevated risk of lung cancer.